dysfunction

(redirected from coronary microvascular dysfunction)
Also found in: Thesaurus, Medical, Financial, Encyclopedia.
Related to coronary microvascular dysfunction: coronary microvascular disease

dys·func·tion

 (dĭs-fŭngk′shən)
n.
1. Abnormal or impaired functioning of a bodily system or organ.
2. Failure to achieve or sustain a behavioral norm or expected condition, as in a social relationship.

dys·func′tion·al adj.

dysfunction

(dɪsˈfʌŋkʃən)
n
1. (Medicine) med any disturbance or abnormality in the function of an organ or part
2. (esp of a family) failure to show the characteristics or fulfil the purposes accepted as normal or beneficial

dys•func•tion

(dɪsˈfʌŋk ʃən)

n.
1. impairment of function or malfunctioning, as of an organ or structure of the body.
2. a consequence of a social activity or structure that undermines a social system.
[1915–20]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.dysfunction - (medicine) any disturbance in the functioning of an organ or body part or a disturbance in the functioning of a social group; "erectile dysfunction"; "sexual relationship dysfunction"
medical specialty, medicine - the branches of medical science that deal with nonsurgical techniques
ED, erectile dysfunction, male erecticle dysfunction - impotence resulting from a man's inability to have or maintain an erection of his penis
pathology - any deviation from a healthy or normal condition
palsy, paralysis - loss of the ability to move a body part
Translations

dysfunction

[dɪsˈfʌŋkʃən] Ndisfunción f

dysfunction

[dɪsˈfʌŋkʃən] n
(behavioural, emotional)dysfonction f
(physical)dysfonction f

dysfunction

nFunktionsstörung f, → Fehlfunktion f; liver dysfunctionFunktionsstörung fder Leber

dys·func·tion

n. desorden, trastorno, malfuncionamiento de un órgano o parte.

dysfunction

n disfunción f; diastolic — disfunción diastólica; erectile — (ED) disfunción eréctil; temporomandibular joint — disfunción temporomandibular, disfunción de la articulación temporomandibular dysfunctional adj disfuncional
References in periodicals archive ?
for the treatment of coronary microvascular dysfunction and CLBS14, recipient of a RMAT designation in the U.S.
Caladrius Biosciences announced the completion of enrollment and dosing in the Phase 2 ESCaPE-CMD study for CLBS16 in patients with coronary microvascular dysfunction. The company expects to announce topline results shortly after the last patient completes follow up at the end of 2019.